Acumed entered into an agreement to be the exclusive distributor of Vivorte’s orthobiologic portfolio, comprising Trabexus calcium phosphate-based bone allograft and Fortera calcium phosphate-based biocement.
Vivorte will continue to utilize its product development and manufacturing capabilities to support distribution. The company first launched Fortera in 2017.
Trabexus is a self-setting matrix with engineered allograft bone particles for optimal compressive strength and resorption, while osteoconductive Fortera combines high compressive strength with superior flow characteristics.
“As a leader in the orthopaedic sector, Acumed is committed to providing the most comprehensive clinical solutions to our surgeons and this partnership with Vivorte allows us to deliver a best-in-class portfolio of orthobiologic technologies,” said Jagi Gill, Vice President/General Manager of AcuVentures at Acumed. “The Trabexus and Fortera products provide our surgeons the distinguishing features of ease of use, strength, and remodeling that are requisite in premier bone allografts and bone void fillers.”
Mark Wagner, CEO of Vivorte, commented, “We have been pleased with the strong clinical support and adoption of our products in the market. Partnering with Acumed, we will reach more surgeons to the benefit of more patients, thereby extending the commercial footprint for our orthobiologic technologies. This works because the two companies share a common vision of delivering innovative solutions in a quality-first culture.”
Acumed entered into an agreement to be the exclusive distributor of Vivorte's orthobiologic portfolio, comprising Trabexus calcium phosphate-based bone allograft and Fortera calcium phosphate-based biocement.
Vivorte will continue to utilize its product development and manufacturing capabilities to support distribution. The...
Acumed entered into an agreement to be the exclusive distributor of Vivorte’s orthobiologic portfolio, comprising Trabexus calcium phosphate-based bone allograft and Fortera calcium phosphate-based biocement.
Vivorte will continue to utilize its product development and manufacturing capabilities to support distribution. The company first launched Fortera in 2017.
Trabexus is a self-setting matrix with engineered allograft bone particles for optimal compressive strength and resorption, while osteoconductive Fortera combines high compressive strength with superior flow characteristics.
“As a leader in the orthopaedic sector, Acumed is committed to providing the most comprehensive clinical solutions to our surgeons and this partnership with Vivorte allows us to deliver a best-in-class portfolio of orthobiologic technologies,” said Jagi Gill, Vice President/General Manager of AcuVentures at Acumed. “The Trabexus and Fortera products provide our surgeons the distinguishing features of ease of use, strength, and remodeling that are requisite in premier bone allografts and bone void fillers.”
Mark Wagner, CEO of Vivorte, commented, “We have been pleased with the strong clinical support and adoption of our products in the market. Partnering with Acumed, we will reach more surgeons to the benefit of more patients, thereby extending the commercial footprint for our orthobiologic technologies. This works because the two companies share a common vision of delivering innovative solutions in a quality-first culture.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
